RxDoctor Payments Data

Samuel Jean, MD

Internal Medicine · Longwood, FLNPI 1730276783

Payments from drug & device makers

$1,435in general payments, 2019–2025

Across 61 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$287
  • Lilly USA, LLC$241
  • Boehringer Ingelheim$148
  • Novo Nordisk$141
  • Johnson & Johnson$110
  • AstraZeneca$98
  • plus $411 from 6 others

What the payments were for

  • Food & beverage$1,435100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,435 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$482,693
Medicare patients
379
Services billed
5,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban148$114,033
OzempicSemaglutide33$66,982
MounjaroTirzepatide23$29,927
JardianceEmpagliflozin29$29,902
RybelsusSemaglutide15$25,094
Soliqua 100-33Insulin Glargine/Lixisenatide12$20,939
EntrestoSacubitril/Valsartan21$20,061
JanuviaSitagliptin Phosphate11$17,027
FarxigaDapagliflozin Propanediol21$15,390
GlyxambiEmpagliflozin/Linagliptin13$15,307
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen122$5,629
LantusInsulin Glargine,hum.Rec.Anlog17$5,078
Albuterol Sulfate HfaAlbuterol Sulfate60$2,532
Clonidine28$2,320
Levothyroxine Sodium243$2,280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$141$92,07548 claims
Boehringer IngelheimJardiance, Glyxambi$148$45,20942 claims
Lilly USA, LLCMounjaro$241$29,92723 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$91$26,01729 claims
AstraZenecaFarxiga$98$15,39021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Longwood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →